Issue Notification: US Patent Update

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the United States Patent and Trademark Office (the "U.S. Patent Office") has published a patent issue notification (the "Issue Notification") in respect of the Company's patent application no. 17/287,441 (the "Patent Application"). A patent issue notification is a document informing an applicant that their patent application has been approved and is scheduled to be granted. The Issue Notification indicates that the patent will be granted on 5 August 2025.

The Patent Application, entitled "Antibody Library and Method", concerns the library of antibodies that is currently screened within Fusion's OptiMAL® platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide "Opti" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation.

Further patent applications and examination processes are continuing in several other territories worldwide including Europe, China and Japan.

Adrian Kinkaid, CEO of Fusion, said: "This news takes us another step forward in gaining patent protection for our Opti discovery platforms including OptiMAL®. Whilst the patent itself has not yet granted, we are excited to have taken a further step toward this important milestone which we believe would represent significant value creation for the business."

We encourage all investors to share questions on this announcement via our investor hub https://investorhub.fusionantibodies.com/link/Pbnn4P